Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How AI and ML Are Scaling Data Collection to Transform Medical Monitoring
Steve Kent, is the Chief Product Officer at Know Labs.
https://www.unite.ai/how-ai-and-ml-are-scaling-data-collection-to-transform-medical-monitoring/
Know Labs Transforming Non-Invasive Medical Diagnostics
https://tinyurl.com/2wjcy3f9
$KNW at 52 week lows right before they are about to do a huge offering. You love to see it with this scam, check our website for the report.
KNW long term pumpers Guido and Core, I hope you guys learned your lesson.
$KNW at 52 week lows right before they are about to do a huge offering. You love to see it with this scam, check our website for the report.
— White Diamond (@WhiteResearch) September 13, 2023
KNW long term pumpers Guido and Core, I hope you guys learned your lesson.
Apple Taps New Leader for Team Developing Glucose Tracker
https://www.bloomberg.com/news/articles/2023-09-14/apple-taps-new-chief-for-team-developing-watch-s-glucose-tracker
The Common Stock began trading on the NYSE American under the symbol "KNW" on September 16, 2022.
https://finance.yahoo.com/news/know-labs-inc-announces-closing-160100588.html
Know Labs, Inc. was up listed to the NYSE American and its been down hill ever since.
Know Labs, Inc. - Developing a Non-Invasive Blood Glucose Monitoring
Know Labs, Inc | Ron Erickson | Benzinga All Access
The Rise Of Glucose Monitoring Among Non-Diabetics
Phil Bosua
Developing big ideas around AI technologies to help/change the world
Joined a struggling company and created a brand new technology platform with the ability to detect blood glucose non-invasively using radio frequencies. As CEO, I oversaw the growth of the company from $0.09 as an OTC stock to an NYSE listing trading above $2.00. Invented and led the development of the hardware, firmware, software and data science algorithms into a working miniaturized prototype for the successful detection and correlated changes of in vivo analytes (blood glucose, oxygen, blood alcohol and more) and in vitro molecular structures to ~500 ppm, verified by world class 3rd party institution, in a device that will cost <$100 to produce. Inventor on 90+ patents issued and pending, positioning the company as the top worldwide IP holder in non-invasive blood glucose monitoring. I highly value the time I spent at Know Labs and the people I worked with.
https://www.linkedin.com/in/philbosua/
Bloomberg: Blood glucose measurement feature won't appear on Apple Watch until 3-7 years from now
https://gagadget.com/en/228989-bloomberg-blood-glucose-measurement-feature-wont-appear-on-apple-watch-until-3-7-years-from-now-amp/
FYI
ITEM 2. PROPERTIES.
Lab Facilities and Executive Offices
On September 22, 2022, we leased lab facilities and executive offices at 58969 Carmelita Circle, Yucca Valley, CA 92284 from Phillip Bosua, our CEO.
We lease 1,700 square feet of the total 2,134 square feet of the premises and the current net monthly payment is $7,000. The lease expires September 30,
2023 and can be extended on a month to month basis. We paid $91,500 in rent on September 28, 2022 for the period September 1, 2021 to September 30,
2022.
FYI - Know Labs Is An Obvious Medical Device Scam, We’re Calling: “Theranos’ Retarded Cousin”
https://whitediamondresearch.com/research/know-labs-is-an-obvious-medical-device-scam-we-call-it-theranos-retarded-cousin/
Say Hello to the Amazing New Dexcom G7
2nd Annual Bernstein CGM Disruptors Conference
November 18, 2022
https://www.knowlabs.co/_files/ugd/23f159_aecb0c42843f43ecb339b848b65620a0.pdf
This Company Reports Moving Toward FDA Approval To Provide Pain-Free Diabetes Monitoring
https://www.benzinga.com/general/biotech/22/08/28431449/this-company-reports-moving-toward-fda-approval-to-provide-pain-free-diabetes-monitoring
Know Labs Inc.
KNWN
, an emerging developer in noninvasive medical diagnostics, focuses on developing its proprietary spectroscopic technologies using the electromagnetic spectrum. The goal is to accurately identify and measure a wide range of organic and inorganic materials, molecules and compositions of matter.
Know Labs’ technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It refers to its technology as Bio-RFID™, which can be integrated into various wearable, mobile or bench-top devices. The company’s patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive, expensive and time-consuming lab-based tests.
The first application of its Bio-RFID technology will reportedly be in a product marketed as a noninvasive glucose monitor, giving the user real-time information on blood glucose levels.
Know Labs’ leadership says it's confident it will be the first company to bring an FDA-cleared noninvasive glucose monitoring device to market. Know Labs is conducting a 200-person internal clinical trial of Bio-RFID, which will help the company refine its algorithm and demonstrate Bio-RFID’s accuracy in a large population... Previous internal tests demonstrated Bio-RFID has accuracy on par or better than currently available solutions, which is an important step toward FDA submission.
For more information on Know Labs Inc., visit knowlabs.co.
Know Labs, Inc.
3,000,000 Shares of Common Stock
This is a firm commitment public offering. We are offering 3,000,000 shares of our common stock, par value $0.001 per share. We currently estimate that the public offering price will be $2.00 per share.
Our common stock is presently traded on the OTC Market Group Inc.’s QB tier, or OTCQB, under the symbol “KNWN.” We plan to apply to have our common stock listed on NYSE American under the symbol “KNW,” which listing is a condition to this offering. No assurance can be given that our application will be approved. On July 26, 2022, the last reported sales price for our common stock as quoted on the OTCQB was $2.14 per share.
https://app.quotemedia.com/data/downloadFiling?webmasterId=102291&ref=116852046&type=HTML&symbol=KNWN&companyName=Know+Labs+Inc&formType=S-1&formDescription=Registration+statement+under+Securities+Act+of+1933&dateFiled=2022-07-29&CK=1074828
FYI July 2022 Know Labs Inc. Investors Presentation
https://www.knowlabs.co/_files/ugd/23f159_ec23baa41800460cab500921c11e2beb.pdf
FYI - Rockley Photonics Holdings
We are short Rockley Photonics $RKLY. We believe the company is experiencing technological roadblocks and will soon face a cash crunch and heavy dilution. 1/13 pic.twitter.com/zt1cSWDTmz
— Iceberg Research (@IcebergResear) April 22, 2022
Bio-RFID Explainer and Other Potential Diagnostics Applications
Know Labs: Little-Known But Highly Capable Company In The MedTech Industry
https://seekingalpha.com/article/4482672-know-labs-little-known-highly-capable-medtech-stock?mailingid=26544482&messageid=2800&serial=26544482.183&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=26544482.183
Rockley Photonics Holdings has announced the successful completion of the first human studies trial
https://www.notebookcheck.net/Ambitious-VitalSpex-non-invasive-blood-sugar-and-blood-pressure-wrist-based-sensing-platform-passes-first-human-trials.595064.0.html
ockley Photonics Holdings has announced the successful completion of the first human studies trial for its biomarker sensing platform. Future VitalSpex modules should be able to non-invasively provide data about biomarkers such as blood alcohol content, blood pressure, and blood sugar. Rockley is also known for its association with Apple.
Medicare Expands Continuous Glucose Monitor (CGM) Coverage
https://www.healthline.com/diabetesmine/medicare-expands-cgm-coverage
Babbage: The smartwatch will see you now
https://open.spotify.com/episode/4Gc8Cj88s9yvCM5UKKO3mx
A new tech boom is disrupting medicine. We investigate how wearable trackers, such as the Fitbit or Apple Watch, could transform health care. And, could the devices help prevent the next pandemic?
Takeaways from Needham Growth Conference Rockley Photonics Holdings Ltd
https://www.reddit.com/r/rkly/comments/s3bd0q/takeaways_from_needham_growth_conference_1132022/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Rockley hired an additional 100 people since the last headcount, now at 302.
Rockley expanded their form factor to include patches in addition to smart watches and wrist bands.
Rockley showed lab verification results for its sensing technology based on tissue phantoms for ethanol, glucose, albumin, urea, creatinine, and water.
Rockley’s next human study results will be for blood pressure followed by hydration, and then alcohol and glucose indicator.
Rockley currently has an IRB-approved pilot human study in progress for blood pressure. Early results show strong correlation with blood pressure cuff measurements.
Rockley currently has a preliminary IRB-approved human study in progress for hydration. Early results show effective discrimination between hydrated and dehydrated body states.
Rockley has a peer-reviewed study on alcohol and early results on glucose indicator show good performance.
Initial commercial volumes of baseline module and band still on track to ship 2H 2022.
Crossbeats Ignite S4
Blood Glucose Monitor
https://www.republicworld.com/amp/web-stories/crossbeats-ignite-s4-comes-with-a-blood-glucose-monitor-check-specs-and-price-3670.html
Dexcom CEO touts unprecedented performance of G7 in clinical trial, awaits FDA decision
https://www.drugdeliverybusiness.com/dexcom-ceo-touts-unprecedented-performance-of-g7-in-clinical-trial-awaits-fda-decision/
Exciting new data for the next-generation Dexcom (NSDQ:DXCM) G7 continuous glucose monitor (CGM) surprised even the company’s leadership.
“The performance of this product is something I never really thought I would see in nearly 30 years in this business,” Sayer said during his J.P. Morgan presentation.
G7 features a 60% size reduction from the G6, a 30-minute warmup period, more information in one place with personalized insights, extended-wear design and more.
Data presented by Sayer and Dexcom highlighted strong performance to accompany the new and improved features of the next-generation technology. G7 outperformed ICGM standards established by the FDA across the board with its time-in-range performance, including overall time-in-range (measured by percentage within 20%) with a tally of 93.3% compared to the FDA standard of 87%.
Mean absolute relative difference (MARD) for G7 registered at 8.1% in pediatric patients and 8.2% in adult patients, highlighting consistency to accompany performance.
Report: Apple still several years away from adding major new health sensors to Apple Watch
https://9to5mac.com/2022/01/09/report-apple-still-several-years-away-from-adding-major-new-health-sensors-to-apple-watch/amp/
If the Apple Watch Series 7 disappointed many for its lack of new sensors, don’t expect things to improve anytime soon. A new report indicates that Apple is still several years away from bringing major new health sensors to the Apple Watch.
In the latest Power On newsletter, Bloomberg’s Mark Gurman talks about what sensors Apple is developing for the Apple Watch and when we’ll see them landing in the actual product. His answer, unfortunately, is not very good for those waiting for a new smartwatch.
Gurman says there are three big new features in the works: glucose/blood sugar monitoring, the ability to take blood pressure, and determining body temperature. All of these sensors have been rumored for a while, and we extensively covered them, here, at 9to5Mac.
Bloomberg’s isn’t convinced that these features will launch anytime soon on a new Apple Watch:
Rockley Photonics #3
#3: Applications and Use Cases for Digital Healthcare and Wearables
https://rockleyphotonics.com/briefing-notes-ces-22-3/
Tracking multiple biomarkers enables a holistic approach to health and wellness
Rockley Photonics #2
#2: Technology Trends for Digital Healthcare and Wearables
https://rockleyphotonics.com/briefing-notes-ces-22-2/
Why photonics-based sensing is a game-changer for wearables
Rockley Photonics
#1: Market Trends for Digital Healthcare and Wearables
https://rockleyphotonics.com/briefing-notes-ces-22-1/
Blurred lines between consumer and medical devices can cut time-to-market for wearables manufacturers
Abbott tells CES it’s getting into consumer biowearables
https://techcrunch.com/2022/01/07/abbott-lingo/amp/
The company has been making continuous glucose monitor (CGM) hardware for diabetes management for years (since 2014) — but in a healthtech keynote at CES yesterday, Abbott’s chairman and CEO, Robert B. Ford, announced it’s developing a new line of consumer biowearables — called Lingo — intended for more general fitness and wellness purposes.
“Technology gives us the power to digitize, decentralize and democratize healthcare, create a shared language between you and your doctor — and put more control of your health in your hands,” he said during the keynote. “We’re creating a future that will bring you and your loved ones care that’s more personal and precise. It’s happening right now. And its potential is no less than incredible.”
Ford said the Lingo sensing technology is being designed to track “key signals” in the body — such as glucose, ketones and lactate — adding that it could also be used to track alcohol levels in the future.
Senseonics Holdings, Inc. (SENS)
13:45 SENS (2.97 +10.82%): Announced operational updates and reaffirmed its FY21 revs guidance. Co is confident that a decision regarding approval of its 180-day CGM system will be made in the coming weeks as the FDA continues to clear a backlog of filings.
Three new additional Videos posted on Youtube from Know, Labs.
https://www.youtube.com/c/KnowLabs/videos
Real-Time, Non-Invasive Biomarker Sensing on the Wrist
https://rockleyphotonics.com/wp-content/uploads/2021/07/Rockley-Photonics-Biomarker-Sensing-on-the-Wrist.pdf
Rockley Photonics Investor Presentation November 2021
https://s28.q4cdn.com/749577678/files/doc_presentation/2021/12/RKLY-3Q21-Investor-Presentation.pdf
Know Labs, Inc. - Tweet
"Today, a few companies that look promising to make a breakthrough in noninvasive glucose monitoring include Know Labs, LifePlus, and Waveform."https://t.co/QJkksP9r9T
— Know Labs - $KNW (@TheKnowLabs) December 16, 2021